References

1. Klein SM, Elmer GW, McFarland LV, Surawicz CM, Levy RH (1993) Recovery and elimination of the biotherapeutic agent, Saccharomycesboulardii, in healthy human volunteers. Pharm Res 10: 1615-1619.
2. Vandenplas Y, Brunser O, Szajewska H (2009) Saccharomyces boulardii in childhood. Eur J Pediatr 168: 253-265.
3. IMS Data 2010.
4. Buts JP, Bernasconi P, Van Craynest MP, Maldague P, De Meyer R (1986) Response of human and rat small intestinal mucosa to oral administration of Saccharomyces boulardii. Pediatr Res 20: 192-196.
5. Swidsinski A, Loening-Baucke V, Verstraelen H, Osowska S, Doerffel Y (2008) Biostructure of fecal microbiota in healthy subjects and patients with chronic idiopathic diarrhea. Gastroenterology: 135(2): 568-57.
6. Joint FAO/WHO Working Group on Drafting Guidelines for the Evaluation of Probiotics in Food (2008) Guidelines for the Evaluation of Probiotics in Food. London Ontario, Canada: FAO/WHO.
7. Schneider SM, Girard-Pipau F, Filippi J, Hebuterne X, Moyse D, et al. (2005) Effects of Saccharomyces boulardii on fecal short-chain fatty acids and microflora in patients on long-term total enteral nutrition. World J Gastroenterol 11: 6165-6169. 
8. Martins FS, Silva AA, Vieira AT, Barbosa FH, Arantes RM, et al. (2009) Comparative study of Bifidobacterium animalis, Escherichia coli, Lactobacillus casei and Saccharomyces boulardii probiotic properties. Arch Microbiol 191: 623-630.
9. Miceli MH, Diaz JA, Lee SA (2011) Emerging opportunistic yeast infections. Lancet Infect Dis 11: 142-151.

« Back to previous page